Methylprednisolone Addition in IVF Treatment of Infertile Couples

Universitair Ziekenhuis Brussel

Status and phase: Unknown; Phase 4

Conditions: In Vitro Fertilization

Treatments: Other: In vitro fertilization treatment for infertility

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01220791

Medrol005

Details and patient eligibility

About

Hypothesis to be tested is whether follicular addition of Methylprednisolone can efficiently control late follicular progesterone rise during IVF treatment

Full description

The aim is to investigate any potential advantages of adding cortisone supplementation from the follicular phase onwards with regard to premature luteinization, oocyte quality, embryo quality and pregnancy outcome.

Enrollment: 130 estimated patients

Sex: Female

Ages: 21 to 36 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• less than 36, more than 10 antral follicles, FSH<12

Exclusion criteria

• endometriosis stage III&IV,

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

130 participants in 2 patient groups, including a placebo group

Follicular Medrol

Active Comparator group

Description:

In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval

Treatment:

Other: In vitro fertilization treatment for infertility

No medrol group

Placebo Comparator group

Description:

Patients will receive only Antagonist protocol for IVF as usual

Treatment:

Other: In vitro fertilization treatment for infertility